Chunmei Wu1†
Yinglu Wang1†Shenshen Chen1Yanwei Lin1
Fang Du1Xiaodong Wang1Sheng Chen1
Liangjing Lu1
Shuang Ye1
Huihua Ding1*
Qiong Fu1,2*- 1Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 2Shanghai Immune Therapy Institute, Shanghai, China
A Correction on
Obinutuzumab in systemic lupus erythematosus: a real-world experience
By Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H and Fu Q (2025) Front. Immunol. 16:1702550. doi: 10.3389/fimmu.2025.1702550
There was a mistake in Table 1 as published. The percentage given for the ‘Relapsing’ column was erroneously written as “27 (55.4)”. This has been corrected to read “27 (48.2)”. The percentage given for the “musculoskeletal involvement” column was erroneously written as “9 (16.1)”. This has been corrected to read “10 (17.9)”. The corrected Table 1 appears below.
Table 1. Baseline characteristics of SLE patients treated with obinutuzumab.
In the Abstract, two percentages were reported incorrectly in the first sentence of the Results section. This has been corrected to read:
“At baseline, 35.7% of patients were newly diagnosed, 55.4% had relapsing/refractory disease, and 8.9% were on maintenance therapy.”
A correction has been made to section Results, paragraph 2, to change “Besdieds” to “Besides”:
“Besides, antidsDNA antibody levels decreased, while complement levels exhibited a notable upward trend throughout the follow-up period.”
A correction has been made to section Results, paragraph 2, to change maitained” to “maintained”:
“Subgroups analysis revealed that all three subgroups, especially the new-onset and relapsing/refractory groups, showed a rapid decrease in SLEDAI-2K scores, which were maintained at low levels through week 48.”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: systemic lupus - erythematosus, obinutuzumab, biologics, real world study, B cell depletion
Citation: Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H and Fu Q (2025) Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience. Front. Immunol. 16:1764419. doi: 10.3389/fimmu.2025.1764419
Received: 10 December 2025; Accepted: 11 December 2025; Revised: 10 December 2025;
Published: 16 December 2025.
Edited and reviewed by:
Luis Ignacio Gonzalez-Granado, University Hospital October 12, SpainCopyright © 2025 Wu, Wang, Chen, Lin, Du, Wang, Chen, Lu, Ye, Ding and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huihua Ding, ZGluZ2h1aWh1YUBvdXRsb29rLmNvbQ==; Qiong Fu, ZnVxaW9uZzVAMTYzLmNvbQ==
†These authors are co-first authors and contribute equally to this paper